Evidence map›Paper›PMID 38966601›Full record

ArticleThe Lancet regional health. Western Pacific2024

Evaluating a novel model of hepatitis B care, Hep B PAST, in the Northern Territory of Australia: results from a prospective, population-based study.

Kelly Hosking, Paula Binks, Teresa De Santis, Phillip Merrdi Wilson, George Garambaka Gurruwiwi, Sarah Mariyalawuy Bukulatjpi, Emily Vintour-Cesar, Melita McKinnon, Peter Nihill, Tammy-Allyn Fernandes and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet regional health. Western Pacific, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. [APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Kelly HoskingNorthern Territory Health, Northern Territory, Australia.
Paula BinksGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Teresa De SantisNorthern Territory Health, Northern Territory, Australia.
Phillip Merrdi WilsonNorthern Territory Health, Northern Territory, Australia.
George Garambaka GurruwiwiGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Sarah Mariyalawuy BukulatjpiMiwatj Aboriginal Health Corporation, Nhulunbuy, East Arnhem Land, Northern Territory, Australia.
Emily Vintour-CesarGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Melita McKinnonGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Peter NihillNorthern Territory Health, Northern Territory, Australia.
Tammy-Allyn FernandesNorthern Territory Health, Northern Territory, Australia.
Belinda Greenwood-SmithNorthern Territory Health, Northern Territory, Australia.
Robert BateyNorthern Territory Health, Northern Territory, Australia.
Cheryl RossGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Steven Y C TongGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Geoffrey StewartNorthern Territory Health, Northern Territory, Australia.
Catherine MarshallNorthern Territory Health, Northern Territory, Australia.
Catherine GarganNorthern Territory Health, Northern Territory, Australia.
Prashanti ManchikantiMiwatj Aboriginal Health Corporation, Nhulunbuy, East Arnhem Land, Northern Territory, Australia.
Karen FullerKatherine West Health Board, Katherine, Northern Territory, Australia.
Jaclyn Tate-BakerNorthern Territory Health, Northern Territory, Australia.
Sami StewartAustralasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, Sydney, NSW, Australia.
Benjamin CowieWHO Collaborating Centre for Viral Hepatitis, The Doherty Institute, Victoria, Australia.
Nicole AllardWHO Collaborating Centre for Viral Hepatitis, The Doherty Institute, Victoria, Australia.
Jennifer H MacLachlanWHO Collaborating Centre for Viral Hepatitis, The Doherty Institute, Victoria, Australia.
Ashleigh QamaWHO Collaborating Centre for Viral Hepatitis, The Doherty Institute, Victoria, Australia.
David BoettigerGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Joshua S DavisGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Christine ConnorsNorthern Territory Health, Northern Territory, Australia.
Jane DaviesNorthern Territory Health, Northern Territory, Australia.
Hep B PAST partnership

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The Northern Territory (NT) has the highest prevalence of chronic hepatitis B (CHB) in Australia. The Hep B PAST program aims to improve health outcomes for people living with CHB. Methods: This mixed methods study involves First Nations peoples living in the NT. We used participatory action research principles across three steps: 1. Foundation step: establishing hepatitis B virus (HBV) status and linkage to care; 2. Capacity building: training the health workforce; 3. Supported transition to primary healthcare: implementation of the "Hub and Spoke" model and in-language resources. Analysis occurred at three time points: 1. Pre-Hep B PAST (2018); 2. Foundation step (2020); and 3. Completion of Hep B PAST (2023). Evaluation focuses on four key indicators, the number of people: 1) with documented HBV status; 2) diagnosed with CHB; 3) receiving care; and 4) receiving treatment. Findings: Hep B PAST (2018-23) reached 40,555 people. HBV status was documented in 11% (1192/10,853), 79.2% (26,075/32,915) and 90.8% (28,675/31,588) of people at pre-Hep B PAST, foundation step, and completion respectively. An estimated 99.9% (821/822) of people were diagnosed, 86.3% (709/822) engaged in care, and 24.1% (198/822) on antiviral treatment at completion. CHB prevalence in the study population is 2.6%, decreasing from 6.1% to 0.4% in the pre- and post-vaccination cohorts. Interpretation: Hep B PAST is an effective model of care. Partner health services are exceeding elimination targets. This model could enable other countries to enhance the cascade of care and work towards eliminating HBV. Funding: National Health and Medical Research Council.

Indexed as

Chronic hepatitis BFirst Nations peoplesGlobal public healthHepatitis B virusPrimary healthcare

Identifiers

PMID38966601
PMCPMC11222935

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.